CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
Conditions
Brief summary
\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells. Following lymphodepletion pretreatment, a single infusion of PA3-17 injection will be administered. Blood samples will be collected from the subjects before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations. In addition to the baseline period, the treatment phase will involve efficacy assessments at 4 weeks, 2 months, 3 months, and every 3 months thereafter, up to 24 months post-cell infusion. Tumor assessments will continue until disease progression (PD), initiation of new antitumor treatment, death, unacceptable toxicity, investigator decision, or subject's voluntary withdrawal, whichever occurs first.
Interventions
After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells, followed by lymphodepletion pretreatment and a single infusion of PA3-17 injection.
Sponsors
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age and Gender: ≥18 years old (inclusive), regardless of gender. 2. Survival Expectancy: ≥3 months. 3. Performance Status: ECOG score 0-1. 4. Diagnosis: Confirmed acute T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) according to the WHO fifth edition of the "Classification of Hematopoietic and Lymphoid Tumors," including early T-cell precursor (ETP). 5. Recurrent or Refractory Disease: Subjects with recurrent/refractory T-ALL/LBL (including ETP-ALL/LBL). 6. Screening: Abnormal cells CD7 expression positive. 7. Lesion Assessment: If the subject has only extramedullary lesions, they must have evaluable lesions. 8. Meet the requirements of liver, kidney, heart, and lung functions. 9. No Severe Mental Disorders. 10. Informed Consent: Ability to understand the trial and signed informed consent form.
Exclusion criteria
1. Known to have active or uncontrolled autoimmune diseases; 2. Presence of GvHD; 3. History of malignant tumors other than T-ALL/LBL within the past 5 years, except for adequately treated cervical intraepithelial neoplasia, basal cell or squamous cell skin cancer, locally treated prostate cancer, and ductal carcinoma in situ of the breast after radical surgery; 4. Positive test results for hepatitis B, hepatitis C, syphilis, etc.; 5. Severe heart disease; 6. Unstable systemic diseases as judged by the investigator; 7. Presence of active infection or uncontrollable infection requiring systemic treatment; 8. Pregnant or breastfeeding women, and female subjects planning to conceive within 2 years after cell infusion, or male subjects whose partners plan to conceive within 2 years after cell infusion; 9. Subjects who have received CAR-T therapy or other gene-modified cell therapy before screening; 10. Participation in other clinical studies within 1 month before screening (end date of the last application of unapproved innovative drugs); 11. Evidence of central nervous system involvement at the time of subject screening; 12. Situations judged by the investigator as not suitable for cell preparation; 13. Other circumstances deemed unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy | Three months | Three-month Objective Response Rate (ORR): Proportion of Composite Complete Response Rate (CRc: CR, CRh, CRi, MLFS) and PR |
Countries
China
Contacts
CONTACTXiaojun Huang, MD
CONTACTMingzhi Zhang, MD
Outcome results
None listed